AVEO Oncology’s Post

🔍 Precision Oncology: A Dominant Force in Modern Cancer Care A recent study reveals that out of the 198 oncology drugs approved by the U.S. FDA from 1998 to 2022, a significant 43% were precision oncology therapies. These therapies, guided by biomarker testing, have seen a rapid increase in FDA approvals, especially from 2017 to 2022. Key Insights: 🎯 Precision oncology therapies require genomic biomarker screening for patient selection. 🎯 The rate of FDA approvals for these therapies saw a sharp rise between 2017 and 2022. 🎯 Despite the growth, the clinical impact of precision oncology remains a topic of discussion. However, the study emphasizes its foundational role in current oncology care. Kudos to Debyani Chakravarty, Sarah Phillips Suehnholz, PhD, and the Memorial Sloan Kettering Cancer Center team for their comprehensive research, shedding light on the evolution and significance of precision oncology in cancer care. https://ow.ly/E0pn50PYk4C #Oncology #PrecisionMedicine #CancerResearch #FDAApprovals

“AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs. Under the terms of the transaction, AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 per share in cash. The transaction values ImmunoGen at a total equity value of approximately $10.1 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024, subject to ImmunoGen shareholder approval, regulatory approvals, and other customary closing conditions.” https://lnkd.in/d3Tz9Z8F

Novel Breast Cancer Therapy Datopotamab Deruxtecan by AstraZeneca and Daiichi Sankyo Accepted by FDA AstraZeneca and Daiichi Sankyo's application for the breast cancer therapy datopotamab deruxtecan has been accepted by U.S. regulatory authorities. The therapy shows promise for patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer. The decision on approval is expected in the first quarter of 2025. The therapy demonstrated advancements in progression-free survival compared to traditional chemotherapy options in a Phase III trial. The therapy uses a TROP2-directed DXd antibody-drug conjugate and offers a potential alternative to conventional chemotherapy. The companies are also seeking approval for the therapy in other regions and for other cancers. For more details please click the link! https://lnkd.in/dPqBh4rX #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Emerging Victorious in Oncology 🏆: Lynparza's Trailblazing Journey Continues! In the competitive realm of cancer therapeutics, one contender stands out with remarkable resilience. AstraZeneca and Merck's Lynparza is on course to dominate the PARP inhibitor market, according to GlobalData's latest forecast. Eyeing a staggering $4 billion in sales by 2027, Lynparza is not just leading; it's setting the pace for innovation in cancer treatment 🚀 Since its pioneering FDA approval in 2014 for BRCA-mutated metastatic ovarian cancer, Lynparza has broadened its therapeutic stronghold. With an impressive portfolio covering breast, prostate, pancreatic, and ovarian cancers, it's geared to claim over 68% of the global PARP market share. Lynparza continues to break new ground, with over 100 clinical trials ongoing, each step brings us closer to a future where cancer's shadow recedes ever more into the light ✅ As Lynparza ventures into new trials and AstraZeneca sharpens its focus on next-gen inhibitors like saruparib, the message is clear - the fight against cancer is relentless! 👏🏼 #AstraZeneca #Merck #Lynparza #OncologyInnovation #CancerCareAhead #ClinicalResearch #ClinicalTrials #LifeScience #ElixirAssociates #StaffingPartner

There are a range of advances in clinical development within oncology, driving changes in standard of care and addressing unmet needs. ADCs continue to demonstrate the potential to improve standard of care and next generation ADC technology is emerging. PD-1 inhibitors also continue to advance the standard of care across numerous disease states, as well as rationally designed small molecules, including when both are given in combination with other agents. Both bi-specific T-cell engagers and bi-specific antibodies are emerging to address unmet clinical needs. Radiopharmaceuticals are also showing promise as oncology therapeutic agents. In haematologic malignancy, CAR-T cell therapy continues to improve care.

ASCO 2024 Unveils Major Breakthroughs in Blood Cancer Treatments At the recent ASCO 2024 conference, pharmaceutical companies revealed significant advancements in blood cancer therapies, specifically Antibody-Drug Conjugates (ADCs) and Tyrosine Kinase Inhibitors (TKIs). Novartis' Scemblix, a pioneering TKI for chronic phase CML, demonstrated promising results in a trial, boasting a higher major molecular response rate and lower discontinuation rates due to adverse events compared to standard treatments. Pfizer's ADC, Adcetris, combined with lenalidomide and rituximab, showcased enhanced overall survival and response rates in patients with relapsed or refractory diffuse large B-cell lymphoma. Additionally, GSK's Blenrep, an ADC for multiple myeloma, exhibited positive outcomes in a trial, although it faces market competition and concerns over severe eye toxicity. These findings underscore the ongoing evolution and potential of targeted therapies in combatting blood cancers. # Thank you Paulina Herrera for your submission!

A summary from ASCO 2024. The latest advances in Oncology Clinical Trials from ASCO 2024 according to Labiotech: 1. Giant Pharma present promising Oncology clinical data 2. Big Pharma KRAS inhibitors are yet to meet their mark 3. A number of young Biotech's present encouraging early data 4. Vaccines for cancer treatment and prevention standout at ASCO 2024 5. Cancer detection tests strive for accuracy Read Labiotech.eu's American Society of Clinical Oncology (ASCO) 2024 conference summary here: https://lnkd.in/dGgHVxuY

AstraZeneca and Daiichi Sankyo, Inc. announced positive high-level Phase III results for their TROP2-directed antibody-drug conjugate, with plans for regulatory submissions underway. This is the first phase III results in breast cancer for AstraZeneca and Daiichi Sankyo's datopotamab deruxecan. Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of five lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

Key findings Results showed 198 new oncology drugs approved by the FDA during the study period. Of these, approximately 43% comprised precision oncology drugs that require biomarker testing. Less than half (47.8%) of all approved precision oncology therapies could be considered first-in-class, meaning they targeted a genomic alteration not yet recognized as clinically actionable. The proportion of tumors harboring a clinically actionable alteration matching an FDA-approved standard care therapy increased from 8.9% to 31.6% between 2017 and 2022. Meanwhile, the number of tumors analyzed that did not harbor an actionable molecular target decreased by almost half, from 44.2% to 22.8%.

Tukysa Triumph Boosts Kadcyla, Amid Pfizer's $43B Seagen Move Pfizer's $43B Acquisition of Seagen Marks Stride in HER2-Positive Breast Cancer Treatment. The successful HER2CLIMB-02 trial, combining Seagen's Tukysa with Roche's Kadcyla, enhances antibody-drug conjugate efficacy for previously treated HER2-positive breast cancer. The move counters competition from AstraZeneca and Daiichi Sankyo's Enhertu, raising questions about Tukysa's significance. Seagen's pipeline, including Tukysa, Enhertu, and disitamab vedotin, amplifies intrigue. As Pfizer invests heavily in Seagen amid promising clinical outcomes, the landscape of innovative HER2-positive breast cancer treatments enters a transformative phase. If you're interested in continuing to read the full story and want to stay updated with the Latest Pharma News in USA, visit Pharmtales. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #tukysa #Pfizer https://lnkd.in/duNq8PfH